Savings options for Zepbound - Eli Lilly and Company
Learn more about the Zepbound® savings card (no Gov`t beneficiaries, terms apply), the Zepbound cash option, and LillyDirect™, an online pharmacy solutions option.
Eli Lilly and Company - Zepbound means change
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …
How do I get Zepbound® (tirzepatide) vials? - medical.lilly.com
Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials.1
Zepbound® (tirzepatide) | Eli Lilly and Company
Zepbound (tirzepatide) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off.
Now Approved for Obstructive Sleep Apnea | HCP | Zepbound® …
Learn more about Zepbound® (tirzepatide) approval for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Change starts with Zepbound 1 - Eli Lilly and Company
Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Zepbound contains tirzepatide.
What is Zepbound | Zepbound® (tirzepatide) - Eli Lilly and Company
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...
ND® (ZEHP-bownd) (tirzepatide) injection, for subcutaneous use What is the most important information I should know about ZEPBOU. D? ZEPBOUND may cause serious side effec. ng in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats.
Lilly releases Zepbound® (tirzepatide) single ... - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.